Single-cell sequencing reveals the role of SALL4 in cervical cancer development

Bao Tonghui1, Li Wufen2, Qi Lin3

  • 1Department of Gynecology, Affiliated Hospital of Qinghai University, Xining, 810000, China.

BMC Cancer
|July 2, 2025
PubMed
Abstract

Insights

High expression of SALL4 drives cervical cancer progression. Inhibiting SALL4 effectively suppresses cancer development, showing its potential as a therapeutic target for cervical cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Cervical cancer remains a significant global health challenge.
  • Understanding key molecular drivers is crucial for developing effective therapies.

Purpose of the Study:

  • Investigate the role of SALL4 in cervical cancer development and progression.
  • Assess SALL4's impact on HeLa cell proliferation, migration, and adhesion.
  • Explore SALL4 as a potential therapeutic target for cervical cancer.

Main Methods:

  • Utilized single-cell sequencing and transcriptomic data analysis to assess SALL4 expression.
  • Conducted in vitro and in vivo experiments to evaluate SALL4 inhibition effects.
  • Examined SALL4's regulation of collagen content and fibrosis.

Main Results:

  • High SALL4 expression significantly promoted cervical cancer cell proliferation, migration, and adhesion.
  • SALL4 knockout markedly reduced cell migration, proliferation, and tumor formation in vivo.
  • SALL4 inhibition led to decreased fibrosis levels.

Conclusions:

  • Elevated SALL4 expression accelerates cervical cancer progression.
  • SALL4 inhibition effectively suppresses cervical cancer development.
  • SALL4 is a promising therapeutic target for cervical cancer treatment.